<DOC>
	<DOCNO>NCT00148395</DOCNO>
	<brief_summary>This study want assess different intensive therapy sequence treatment non-small-cell lung cancer . It claim less efficacy different chemotherapy combination , comparison different strategy sequential single-agent , sequential double-agent sequential triple-agent therapy .</brief_summary>
	<brief_title>Randomized Phase III-Study Stage IIIb IV Non-Small-Cell Lung Cancer . Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Histological verify nonsmall cell lung cancer . Cytological diagnosis accept doubtless result . 2 . Present stage IIIb malignant pleural effusion stage IV disease . Tumor dissemination irradiable one field 3 . Age 18 75 year 4 . Karnofsky index 70 100 % 5 . Measurable evaluable tumor parameter 6 . No prior chemotherapy NSCLC 7 . Sufficient hematological parameter start therapy ( leucocytes &gt; 3.500/µl platelet &gt; 100.000/µl ) . 8 . Sufficient liver function ( bilirubin &lt; 1,6mg/dl ) 9 . Sufficient renal function ( creatinine &lt; 1,5mg/dl clearance &gt; 60ml/min ) 10 . Minimal estimate life expectancy &gt; 3 month 11 . Written inform consent study attendance 12 . Patient accessibility therapy follow 13 . No attendance study 1 . Smallcell lung cancer oder tumor smallcell fraction 2 . Local advance irradiable stage III 3 . Previous chemotherapy disease , longer 3 year ago 4 . Simultaneous radiation present tumor manifestation 5 . Simultaneous long 3 year ago secondary malignancy , except carcinoma situ cervix dermal cancer , others melanoma 6 . Respiratory insufficiency 7 . Heart insufficiency NYHA III IV 8 . Peripheral arteriosclerosis stage III IV 9 . Neurological psychiatric disease , affect understand study concept possibility keep condition protocol 10 . Pregnancy , breastfeed ensure contraception 11 . HIVinfection 12 . Active hepatitis B C 13 . Manifest infectious disease start therapy 14 . Minimal estimate life expectancy &lt; 3 month 15 . No write informed consent patient study attendance storage disclosure disease data accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>